REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 9.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 417,739 shares of the biotechnology company’s stock after buying an additional 37,055 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.84% of REGENXBIO worth $4,382,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Maryland State Retirement & Pension System boosted its holdings in REGENXBIO by 7.2% in the second quarter. Maryland State Retirement & Pension System now owns 15,800 shares of the biotechnology company’s stock valued at $185,000 after purchasing an additional 1,067 shares in the last quarter. Amalgamated Bank boosted its holdings in REGENXBIO by 9.9% in the second quarter. Amalgamated Bank now owns 13,613 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,227 shares in the last quarter. Arizona State Retirement System boosted its holdings in REGENXBIO by 20.6% in the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 1,997 shares in the last quarter. nVerses Capital LLC boosted its holdings in REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 2,200 shares in the last quarter. Finally, Louisiana State Employees Retirement System boosted its holdings in REGENXBIO by 14.0% in the second quarter. Louisiana State Employees Retirement System now owns 22,800 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 2,800 shares in the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Argeris N. Karabelas sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the sale, the director now owns 11,286 shares of the company’s stock, valued at approximately $114,101.46. This trade represents a 46.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 13.13% of the company’s stock.

REGENXBIO Stock Down 5.0 %

RGNX opened at $8.28 on Friday. The firm has a market capitalization of $410.19 million, a P/E ratio of -1.65 and a beta of 1.24. The firm’s 50 day moving average is $9.74 and its 200-day moving average is $11.42. REGENXBIO Inc. has a 52-week low of $8.26 and a 52-week high of $28.80.

Analysts Set New Price Targets

RGNX has been the subject of several research reports. HC Wainwright reduced their price target on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Raymond James reiterated an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a report on Thursday, October 10th. Morgan Stanley reissued an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a research note on Friday, November 15th. Chardan Capital reaffirmed a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research note on Wednesday, November 20th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $35.00 price objective on shares of REGENXBIO in a report on Wednesday. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $35.27.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.